Sphingolipids: Membrane microdomains in brain development, function and neurological diseases

Open Biology

Volumn 7, Issue 5, 2017, Pages

  Olsen, Anne S B ^a   Færgeman, Nils J ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Brain; Ganglioside; Membrane microdomain; Neurological disease; Raft; Sphingolipid

Indexed keywords

SPHINGOLIPID;

ANIMAL; BIOLOGICAL MODEL; BRAIN; DEGENERATIVE DISEASE; GROWTH, DEVELOPMENT AND AGING; HUMAN; MEMBRANE MICRODOMAIN; METABOLISM; MYELIN SHEATH; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; HUMANS; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; NEURONS; SPHINGOLIPIDS; SYNAPTIC TRANSMISSION;

EID: 85020045545     PISSN: None     EISSN: 20462441     Source Type: Journal    
DOI: 10.1098/rsob.170069     Document Type: Review

References (191)

1. van Echten-Deckert G, Herget T. 2006 Sphingolipid metabolism in neural cells. Biochim. Biophys. Acta 1758, 1978-1994. (doi: 10.1016/j.bbamem.2006. 06.009
2. Piccinini M et al. 2010 Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders. Mol. Neurobiol. 41, 314-340. (doi: 10.1007/s12035-009-8096-6
3. Aureli M, Grassi S, Prioni S, Sonnino S, Prinetti A. 2015 Lipid membrane domains in the brain. Biochim. Biophys. Acta 1851, 1006-1016. (doi: 10. 1016/j.bbalip.2015.02.001
4. O'Brien JS, Sampson EL. 1965 Lipid composition of the normal human brain: Gray matter, white matter, and myelin. J. Lipid Res. 6, 537-544.
5. Svennerholm L, Vanier MT. 1973 The distribution of lipids in the human nervous system. IV. Fatty acid composition of major sphingolipids of human infant brain. Brain Res. 55, 413-423. (doi: 10.1016/0006-8993(73)90306-5
6. Svennerholm L, Bostrom K, Jungbjer B, Olsson L. 1994 Membrane lipids of adult human brain: Lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J. Neurochem. 63, 1802-1811. (doi: 10.1046/j.1471-4159.1994. 63051802.x
7. Dart C. 2010 Lipid microdomains and the regulation of ion channel function. J. Physiol. 588, 3169-3178. (doi: 10.1113/jphysiol.2010.191585
8. Nicolau Jr DV, Burrage K, Parton RG, Hancock JF. 2006 Identifying optimal lipid raft characteristics required to promote nanoscale protein-protein interactions on the plasma membrane. Mol. Cell. Biol. 26, 313-323. (doi: 10.1128/mcb.26.1.313-323.2006
9. Simons K, Ikonen E. 1997 Functional rafts in cell membranes. Nature 387, 569-572. (doi: 10.1038/42408
10. Lingwood D, Simons K. 2010 Lipid rafts as a membrane-organizing principle. Science 327, 46-50. (doi: 10.1126/science.1174621
11. Saher G, Quintes S, Nave KA. 2011 Cholesterol: A novel regulatory role in myelin formation. The Neuroscientist 17, 79-93. (doi: 10.1177/1073858410373835
12. Pfrieger FW, Ungerer N. 2011 Cholesterol metabolism in neurons and astrocytes. Progr. Lipid Res. 50, 357-371. (doi: 10.1016/j.plipres.2011.06.002
13. Schengrund CL. 2015 Gangliosides: Glycosphingolipids essential for normal neural development and function. Trends Biochem. Sci. 40, 397-406. (doi: 10.1016/j.tibs.2015.03.007
14. Pike LJ. 2004 Lipid rafts: Heterogeneity on the high seas. Biochem. J. 378, 281-292. (doi: 10.1042/bj20031672
15. Razani B, Woodman SE, Lisanti MP. 2002 Caveolae: From cell biology to animal physiology. Pharmacol. Rev. 54, 431-467. (doi: 10.1124/pr.54.3.431
16. Eggeling C et al. 2009 Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457, 1159-1162. (doi: 10.1038/nature07596
17. Ekyalongo RC, Nakayama H, Kina K, Kaga N, Iwabuchi K. 2015 Organization and functions of glycolipid-enriched microdomains in phagocytes. Biochim. Biophys. Acta 1851, 90-97. (doi: 10.1016/j.bbalip.2014.06.009
18. Marin R, Rojo JA, Fabelo N, Fernandez CE, Diaz M. 2013 Lipid raft disarrangement as a result of neuropathological progresses: A novel strategy for early diagnosis? Neuroscience 245, 26-39. (doi: 10. 1016/j.neuroscience.2013.04.025
19. Ohmi Y, Ohkawa Y, Yamauchi Y, Tajima O, Furukawa K, Furukawa K. 2012 Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem. Res. 37, 1185-1191. (doi: 10.1007/s11064-012-0764-7
20. Astudillo L, Sabourdy F, Therville N, Bode H, Segui B, Andrieu-Abadie N, Hornemann T, Levade T. 2015 Human genetic disorders of sphingolipid biosynthesis. J. Inherit. Metab. Dis. 38, 65-76. (doi: 10.1007/s10545-014-9736-1
21. Ong WY, Herr DR, Farooqui T, Ling EA, Farooqui AA. 2015 Role of sphingomyelinases in neurological disorders. Expert Opin. Therapeutic Targets 19, 1725-1742. (doi: 10.1517/14728222.2015.1071794
22. Gault CR, Obeid LM, Hannun YA. 2010 An overview of sphingolipid metabolism: From synthesis to breakdown. Adv. Exp. Med. Biol. 688, 1-23. (doi: 10.1007/978-1-4419-6741-1-1
23. Zheng W et al. 2006 Ceramides and other bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta 1758, 1864-1884. (doi: 10.1016/j.bbamem.2006.08.009
24. Lahiri S, Futerman AH. 2007 The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64, 2270-2284. (doi: 10.1007/s00018-007-7076-0
25. Karlsson KA. 1970 Sphingolipid long chain bases. Lipids 5, 878-891. (doi: 10.1007/BF02531119
26. Sullards MC, Allegood JC, Kelly S, Wang E, Haynes CA, Park H, Chen Y, Merrill Jr AH. 2007 Structurespecific, quantitative methods for analysis of sphingolipids by liquid chromatography-Tandem mass spectrometry: Inside-out' sphingolipidomics. Methods Enzymol. 432, 83-115. (doi: 10.1016/s0076-6879(07)32004-1
27. Merrill Jr AH. 2011 Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 111, 6387-6422. (doi: 10.1021/cr2002917
28. Sandhoff R. 2010 Very long chain sphingolipids: Tissue expression, function and synthesis. FEBS Lett. 584, 1907-1913. (doi: 10.1016/j.febslet.2009.12.032
29. Pruett ST, Bushnev A, Hagedorn K, Adiga M, Haynes CA, Sullards MC, Liotta DC, Merrill Jr AH. 2008 Biodiversity of sphingoid bases ('sphingosines') and related amino alcohols. J. Lipid Res. 49, 1621-1639. (doi: 10.1194/jlr.R800012-JLR200
30. Sonnino S, Chigorno V. 2000 Ganglioside molecular species containing C18-And C20-sphingosine in mammalian nervous tissues and neuronal cell cultures. Biochim. Biophys. Acta 1469, 63-77. (doi: 10.1016/S0005-2736(00)00210-8
31. Hirschberg K, Rodger J, Futerman AH. 1993 The long-chain sphingoid base of sphingolipids is acylated at the cytosolic surface of the endoplasmic reticulum in rat liver. Biochem. J. 290, 751-757. (doi: 10.1042/bj2900751
32. Mandon EC, Ehses I, Rother J, van Echten G, Sandhoff K. 1992 Subcellular localization and membrane topology of serine palmitoyltransferase, 3-dehydrosphinganine reductase, and sphinganine N-Acyltransferase in mouse liver. J. Biol. Chem. 267, 11 144-11 148.
33. Michel C, van Echten-Deckert G. 1997 Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum. FEBS letters. 416, 153-155. (doi: 10.1016/S0014-5793(97)01187-3
34. Michel C, van Echten-Deckert G, Rother J, Sandhoff K, Wang E, Merrill Jr AH. 1997 Characterization of ceramide synthesis: A dihydroceramide desaturase introduces the 4,5-Trans-double bond of sphingosine at the level of dihydroceramide. J. Biol. Chem. 272, 22 432-22 437. (doi: 10.1074/jbc.272. 36.22432
35. Levy M, Futerman AH. 2010 Mammalian ceramide synthases. IUBMB Life 62, 347-356. (doi: 10.1002/iub.319
36. Vacaru AM, Tafesse FG, Ternes P, Kondylis V, Hermansson M, Brouwers JF, Somerharju P, Rabouille C, Holthuis JC. 2009 Sphingomyelin synthase-related protein SMSr controls ceramide homeostasis in the ER. J. Cell Biol. 185, 1013-1027. (doi: 10.1083/jcb.200903152
37. Sprong H, Kruithof B, Leijendekker R, Slot JW, van Meer G, van der Sluijs P. 1998 UDPgalactose: Ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic reticulum. J. Biol. Chem. 273, 25 880-25 888. (doi: 10.1074/jbc.273.40.25880
38. Palmano K, Rowan A, Guillermo R, Guan J, McJarrow P. 2015 The role of gangliosides in neurodevelopment. Nutrients 7, 3891-3913. (doi: 10.3390/nu7053891
39. Valaperta R, Chigorno V, Basso L, Prinetti A, Bresciani R, Preti A, Miyagi T, Sonnino S. 2006 Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J. 20, 1227-1229. (doi: 10.1096/fj.05-5077fje
40. Jenkins RW, Canals D, Hannun YA. 2009 Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell. Signall. 21, 836-846. (doi: 10.1016/j.cellsig.2009. 01.026
41. Tani M, Kuge O. 2009 Sphingomyelin synthase 2 is palmitoylated at the COOH-Terminal tail, which is involved in its localization in plasma membranes. Biochem. Biophys. Res. Commun. 381, 328-332. (doi: 10.1016/j.bbrc.2009.02.063
42. Mullen TD, Hannun YA, Obeid LM. 2012 Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem. J. 441, 789-802. (doi: 10.1042/bj20111626
43. Hannun YA, Obeid LM. 2011 Many ceramides. J. Biol. Chem. 286, 27 855-27 862. (doi: 10.1074/jbc.R111.254359
44. Norton WT, Poduslo SE. 1973 Myelination in rat brain: Changes in myelin composition during brain maturation. J. Neurochem. 21, 759-773. (doi: 10.1111/j.1471-4159.1973.tb07520.x
45. Mansson JE, Vanier MT, Svennerholm L. 1978 Changes in the fatty acid and sphingosine composition of the major gangliosides of human brain with age. J. Neurochem. 30, 273-275. (doi: 10.1111/j.1471-4159.1978. tb07064.x
46. Svennerholm L, Bostrom K, Fredman P, Mansson JE, Rosengren B, Rynmark BM. 1989 Human brain gangliosides: Developmental changes from early fetal stage to advanced age. Biochim. Biophys. Acta 1005, 109-117. (doi: 10.1016/0005-2760(89)90175-6
47. Sastry PS. 1985 Lipids of nervous tissue: Composition and metabolism. Progr. Lipid Res. 24, 69-176. (doi: 10.1016/0163-7827(85)90011-6
48. Norton WT, Autilio LA. 1966 The lipid composition of purified bovine brain myelin. J. Neurochem. 13, 213-222. (doi: 10.1111/j.1471-4159.1966.tb06794.x
49. Posse de Chaves E, Sipione S. 2010 Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 584, 1748-1759. (doi: 10.1016/j.febslet.2009.12.010
50. Tettamanti G. 2004 Ganglioside/glycosphingolipid turnover: New concepts. Glycoconjugate J. 20, 301-317. (doi: 10.1023/B: GLYC.0000033627.02765.cc
51. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G. 1991 Human brain gangliosides in development, aging and disease. Inter. J. Dev. Biol. 35, 289-295.
52. Segler-Stahl K, Webster JC, Brunngraber EG. 1983 Changes in the concentration and composition of human brain gangliosides with aging. Gerontology 29, 161-168. (doi: 10.1159/000213109
53. Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK. 2007 Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem. 103, 2327-2341. (doi: 10.1111/j.1471-4159.2007.04910.x
54. Norton WT, Cammer W. 1977 Isolation and characterization of myelin. New York, NY: Springer.
55. Baumann N, Pham-Dinh D. 2001 Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 81, 871-927.
56. Yamamoto N, Matsubara T, Sato T, Yanagisawa K. 2008 Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid b-protein fibrillogenesis. Biochim. Biophys. Acta 1778, 2717-2726. (doi: 10. 1016/j.bbamem.2008.07.028
57. Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG, Fujita SC, Yanagisawa K. 2004 Accelerated Ab aggregation in the presence of GM1-ganglioside-Accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569, 135-139. (doi: 10.1016/j.febslet. 2004.05.037
58. Yu RK, Macala LJ, Taki T, Weinfield HM, Yu FS. 1988 Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J. Neurochem. 50, 1825-1829. (doi: 10.1111/j.1471-4159.1988. tb02484.x
59. Wang J, Yu RK. 2013 Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc. Natl Acad. Sci. USA 110, 19 137-19 142. (doi: 10.1073/pnas.1307224110
60. Wang J, Cheng A, Wakade C, Yu RK. 2014 Ganglioside GD3 is required for neurogenesis and long-Term maintenance of neural stem cells in the postnatal mouse brain. J. Neurosci. 34, 13 790-13 800. (doi: 10.1523/jneurosci.2275-14.2014
61. Roisen FJ, Bartfeld H, Nagele R, Yorke G. 1981 Ganglioside stimulation of axonal sprouting in vitro. Science 214, 577-578. (doi: 10.1126/science. 7291999
62. Byrne MC, Ledeen RW, Roisen FJ, Yorke G, Sclafani JR. 1983 Ganglioside-induced neuritogenesis: Verification that gangliosides are the active agents, and comparison of molecular species. J. Neurochem. 41, 1214-1222. (doi: 10.1111/j.1471-4159.1983. tb00814.x
63. Wu G, Fang Y, Lu ZH, Ledeen RW. 1998 Induction of axon-like and dendrite-like processes in neuroblastoma cells. J. Neurocytol. 27, 1-14. (doi: 10.1023/A: 1006910001869
64. Ferreira A, Busciglio J, Landa C, Caceres A. 1990 Ganglioside-enhanced neurite growth: Evidence for a selective induction of high-molecular-weight MAP-2. J. Neurosci. 10, 293-302.
65. Vaudry D, Stork PJ, Lazarovici P, Eiden LE. 2002 Signaling pathways for PC12 cell differentiation: Making the right connections. Science 296, 1648-1649. (doi: 10.1126/science.1071552
66. Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N. 1995 Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl Acad. Sci. USA 92, 5087-5091. (doi: 10.1073/pnas.92.11.5087
67. Mutoh T, Tokuda A, Inokuchi J, Kuriyama M. 1998 Glucosylceramide synthase inhibitor inhibits the action of nerve growth factor in PC12 cells. J. Biol. Chem. 273, 26 001-26 007. (doi: 10.1074/jbc.273. 40.26001
68. Farooqui T, Franklin T, Pearl DK, Yates AJ. 1997 Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of TrkA. J. Neurochem. 68, 2348-2355. (doi: 10.1046/j.1471-4159.1997.68062348.x
69. Da Silva JS, Hasegawa T, Miyagi T, Dotti CG, Abad-Rodriguez J. 2005 Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat. Neurosci. 8, 606-615. (doi: 10.1038/nn1442
70. Fukumoto S, Mutoh T, Hasegawa T, Miyazaki H, Okada M, Goto G, Furukawa K, Urano T. 2000 GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J. Biol. Chem. 275, 5832-5838. (doi: 10.1074/jbc.275.8.5832
71. Furukawa K, Ohmi Y, Ohkawa Y, Tajima O, Furukawa K. 2014 Glycosphingolipids in the regulation of the nervous system. Adv. Neurobiol. 9, 307-320. (doi: 10.1007/978-1-4939-1154-7-14
72. Harel R, Futerman AH. 1993 Inhibition of sphingolipid synthesis affects axonal outgrowth in cultured hippocampal neurons. J. Biol. Chem. 268, 14 476-14 481.
73. Schwarz A, Rapaport E, Hirschberg K, Futerman AH. 1995 A regulatory role for sphingolipids in neuronal growth: Inhibition of sphingolipid synthesis and degradation have opposite effects on axonal branching. J. Biol. Chem. 270, 10 990-10 998. (doi: 10.1074/jbc.270.18.10990
74. Campenot RB, Walji AH, Draker DD. 1991 Effects of sphingosine, staurosporine, and phorbol ester on neurites of rat sympathetic neurons growing in compartmented cultures. J. Neurosci. 11, 1126-1139.
75. Furuya S, Ono K, Hirabayashi Y. 1995 Sphingolipid biosynthesis is necessary for dendrite growth and survival of cerebellar Purkinje cells in culture. J. Neurochem. 65, 1551-1561. (doi: 10.1046/j.1471-4159.1995.65041551.x
76. Zhao L, Spassieva SD, Jucius TJ, Shultz LD, Shick HE, Macklin WB, Hannun YA, Obeid LM, Ackerman SL. 2011 A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genetics. 7, e1002063. (doi: 10.1371/journal.pgen.1002063
77. Furuya S, Mitoma J, Makino A, Hirabayashi Y. 1998 Ceramide and its interconvertible metabolite sphingosine function as indispensable lipid factors involved in survival and dendritic differentiation of cerebellar Purkinje cells. J. Neurochem. 71, 366-377. (doi: 10.1046/j.1471-4159.1998.71010366.x
78. Watanabe S, Endo S, Oshima E, Hoshi T, Higashi H, Yamada K, Tohyama K, Yamashita T, Hirabayashi Y. 2010 Glycosphingolipid synthesis in cerebellar Purkinje neurons: Roles in myelin formation and axonal homeostasis. Glia 58, 1197-1207. (doi: 10.1002/glia.20999
79. Spassieva SD, Ji X, Liu Y, Gable K, Bielawski J, Dunn TM, Bieberich E, Zhao L. 2016 Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency. Proc. Natl Acad. Sci. USA 113, 5928-5933. (doi: 10.1073/pnas.1522071113
80. Mendez-Otero R, Santiago MF. 2003 Functional role of a specific ganglioside in neuronal migration and neurite outgrowth. Brazilian J. Med. Biol. Res. 36, 1003-1013.
81. Stojiljkovic M, Blagojevic T, Vukosavic S, Zvezdina ND, Pekovic S, Nikezic G, Rakic L. 1996 Ganglioside GM1 and GM3 in early human brain development: An immunocytochemical study. Int. J. Dev. Neurosci. 14, 35-44. (doi: 10.1016/0736-5748(95)00078-X
82. Hering H, Lin CC, Sheng M. 2003 Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262-3271.
83. van Spronsen M, Hoogenraad CC. 2010 Synapse pathology in psychiatric and neurologic disease. Curr. Neurol. Neurosci. Rep. 10, 207-214. (doi: 10.1007/s11910-010-0104-8
84. Gielen E, Baron W, Vandeven M, Steels P, Hoekstra D, Ameloot M. 2006 Rafts in oligodendrocytes: Evidence and structure-function relationship. Glia 54, 499-512. (doi: 10.1002/glia.20406
85. Susuki K et al. 2007 Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 55, 746-757. (doi: 10.1002/glia.20503
86. Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B. 1998 Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J. Neurosci. 18, 1642-1649.
87. Pan B, Fromholt SE, Hess EJ, Crawford TO, Griffin JW, Sheikh KA, Schnaar RL. 2005 Myelin-Associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: Neuropathology and behavioral deficits in single-And double-null mice. Exp. Neurol. 195, 208-217. (doi: 10.1016/j.expneurol.2005.04.017
88. Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL. 1999 Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl Acad. Sci. USA 96, 7532-7537. (doi: 10.1073/pnas. 96.13.7532
89. Honke K et al. 2002 Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc. Natl Acad. Sci. USA 99, 4227-4232. (doi: 10.1073/pnas.032068299
90. Vyas AA, Patel HV, Fromholt SE, Heffer-Lauc M, Vyas KA, Dang J, Schachner M, Schnaar RL. 2002 Gangliosides are functional nerve cell ligands for myelin-Associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc. Natl Acad. Sci. USA 99, 8412-8417. (doi: 10.1073/pnas.072211699
91. Schnaar RL, Lopez PH. 2009 Myelin-Associated glycoprotein and its axonal receptors. J. Neurosci. Res. 87, 3267-3276. (doi: 10.1002/jnr.21992
92. DeBruin LS, Haines JD, Wellhauser LA, Radeva G, Schonmann V, Bienzle D, Harauz G. 2005 Developmental partitioning of myelin basic protein into membrane microdomains. J. Neurosci. Res. 80, 211-225. (doi: 10.1002/jnr.20452
93. Simons M, Kramer EM, Thiele C, Stoffel W, Trotter J. 2000 Assembly of myelin by association of proteolipid protein with cholesterol-And galactosylceramide-rich membrane domains. J. Cell Biol. 151, 143-154. (doi: 10.1083/jcb.151.1.143
94. Stewart RJ, Boggs JM. 1993 A carbohydratecarbohydrate interaction between galactosylceramide-containing liposomes and cerebroside sulfate-containing liposomes: Dependence on the glycolipid ceramide composition. Biochemistry 32, 10 666-10 674. (doi: 10.1021/bi00091a017
95. Boggs JM, Gao W, Zhao J, Park HJ, Liu Y, Basu A. 2010 Participation of galactosylceramide and sulfatide in glycosynapses between oligodendrocyte or myelin membranes. FEBS Lett. 584, 1771-1778. (doi: 10.1016/j.febslet.2009.11.074
96. Ishibashi T et al. 2002 A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J. Neurosci. 22, 6507-6514. (20026705
97. Schafer DP, Bansal R, Hedstrom KL, Pfeiffer SE, Rasband MN. 2004 Does paranode formation and maintenance require partitioning of neurofascin 155 into lipid rafts? J. Neurosc. 24, 3176-3185. (doi: 10. 1523/jneurosci.5427-03.2004
98. Dupree JL, Girault JA, Popko B. 1999 Axo-glial interactions regulate the localization of axonal paranodal proteins. J. Cell Biol. 147, 1145-1152. (doi: 10.1083/jcb.147.6.1145
99. Ben-David O et al. 2011 Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. J. Biol. Chem. 286, 30 022-30 033. (doi: 10.1074/jbc.M111.261206
100. Chiavegatto S, Sun J, Nelson RJ, Schnaar RL. 2000 A functional role for complex gangliosides: Motor deficits in GM2/GD2 synthase knockout mice. Exp. Neurol. 166, 227-234. (doi: 10.1006/exnr.2000.7504
101. Dotti CG, Esteban JA, Ledesma MD. 2014 Lipid dynamics at dendritic spines. Front. Neuroanat. 8, 76. (doi: 10.3389/fnana.2014.00076
102. Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, Mattson MP, Geiger JD, Haughey NJ. 2009 Tumor necrosis factor-A-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J. Neurochem. 109, 1237-1249. (doi: 10.1111/j.1471-4159.2009.06038.x
103. Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ. 2010 Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J. Neurosci. Res. 88, 2940-2951. (doi: 10. 1002/jnr.22438
104. Gulbins E et al. 2013 Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat. Med. 19, 934-938. (doi: 10.1038/nm.3214
105. Gulbins E et al. 2015 A central role for the acid sphingomyelinase/ceramide system in neurogenesis and major depression. J. Neurochem. 134, 183-192. (doi: 10.1111/jnc.13145
106. Sonnino S, Prinetti A. 2016 The role of sphingolipids in neuronal plasticity of the brain. J. Neurochem. 137, 485-488. (doi: 10.1111/jnc.13589
107. Besshoh S, Bawa D, Teves L, Wallace MC, Gurd JW. 2005 Increased phosphorylation and redistribution of NMDA receptors between synaptic lipid rafts and post-synaptic densities following transient global ischemia in the rat brain. J. Neurochem. 93, 186-194. (doi: 10.1111/j.1471-4159.2004.03009.x
108. Okada Y, Rahmann H, Hirai H, Terashima A. 1994 Exogenously applied gangliosides (GM1, GD1a and Gmix) fail to facilitate the induction of long-Term potentiation (LTP) in the slices of hippocampus and superior colliculus of the guinea pig. Neurosci. Lett. 170, 269-272. (doi: 10.1016/0304-3940(94)90335-2
109. Fujii S et al. 2002 Effects of the mono-And tetrasialogangliosides GM1 and GQ1b on ATPinduced long-Term potentiation in hippocampal CA1 neurons. Glycobiology 12, 339-344. (doi: 10.1093/glycob/12.5.339
110. Shin MK, Jung WR, Kim HG, Roh SE, Kwak CH, Kim CH, Kim SJ, Kim KL. 2014 The ganglioside GQ1b regulates BDNF expression via the NMDA receptor signaling pathway. Neuropharmacology 77, 414-421. (doi: 10.1016/j.neuropharm.2013.10.022
111. Allen JA, Halverson-Tamboli RA, Rasenick MM. 2007 Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128-140. (doi: 10.1038/nrn2059
112. Colon-Saez JO, Yakel JL. 2011 The a7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane. J. Physiol. 589, 3163-3174. (doi: 10.1113/jphysiol.2011.209494
113. Xu Y, Ramu Y, Lu Z. 2008 Removal of phospho-head groups of membrane lipids immobilizes voltage sensors of K+ channels. Nature 451, 826-829. (doi: 10.1038/nature06618
114. Bock J, Szabo I, Gamper N, Adams C, Gulbins E. 2003 Ceramide inhibits the potassium channel Kv1.3 by the formation of membrane platforms. Biochem. Biophys. Res. Commun. 305, 890-897. (doi: 10.1016/S0006-291X(03)00763-0
115. Martens JR, Sakamoto N, Sullivan SA, Grobaski TD, Tamkun MM. 2001 Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations: Targeting of Kv1.5 to caveolae. J. Biol. Chem. 276, 8409-8414. (doi: 10.1074/jbc. M009948200
116. Milescu M, Bosmans F, Lee S, Alabi AA, Kim JI, Swartz KJ. 2009 Interactions between lipids and voltage sensor paddles detected with tarantula toxins. Nat. Struct. Mol. Biol. 16, 1080-1085. (doi: 10.1038/nsmb.1679
117. Ramu Y, Xu Y, Lu Z. 2006 Enzymatic activation of voltage-gated potassium channels. Nature 442, 696-699. (doi: 10.1038/nature04880
118. 2+-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals. Pharmacol. Res. 100, 101-116. (doi: 10.1016/j.phrs.2015.07.028
119. Szoke E, Borzsei R, Toth DM, Lengl O, Helyes Z, Sandor Z, Szolcsanyi J. 2010 Effect of lipid raft disruption on TRPV1 receptor activation of trigeminal sensory neurons and transfected cell line. Eur. J. Pharmacol. 628, 67-74. (doi: 10.1016/j. ejphar.2009.11.052
120. Yang SN. 2000 Ceramide-induced sustained depression of synaptic currents mediated by ionotropic glutamate receptors in the hippocampus: An essential role of postsynaptic protein phosphatases. Neuroscience 96, 253-258. (doi: 10. 1016/S0306-4522(99)00582-5
121. Attiori Essis S, Laurier-Laurin ME, Pepin E, Cyr M, Massicotte G. 2015 GluN2B-containing NMDA receptors are upregulated in plasma membranes by the sphingosine-1-phosphate analog FTY720P. Brain Res. 1624, 349-358. (doi: 10.1016/j.brainres.2015. 07.055
122. Paila YD, Ganguly S, Chattopadhyay A. 2010 Metabolic depletion of sphingolipids impairs ligand binding and signaling of human serotonin1A receptors. Biochemistry 49, 2389-2397. (doi: 10. 1021/bi1001536
123. Sjogren B, Svenningsson P. 2007 Depletion of the lipid raft constituents, sphingomyelin and ganglioside, decreases serotonin binding at human 5-HT7(a) receptors in HeLa cells. Acta Physiol. 190, 47-53. (doi: 10.1111/j.1365-201X.2007.01687.x
124. Park JW, Park WJ, Kuperman Y, Boura-Halfon S, Pewzner-Jung Y, Futerman AH. 2013 Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergentresistant membranes. Hepatology 57, 525-532. (doi: 10.1002/hep.26015
125. Vainio S, Heino S, Mansson JE, Fredman P, Kuismanen E, Vaarala O, Ikonen E. 2002 Dynamic association of human insulin receptor with lipid rafts in cells lacking caveolae. EMBO Rep. 3, 95-100. (doi: 10.1093/embo-reports/kvf010
126. Kabayama K, Sato T, Kitamura F, Uemura S, Kang BW, Igarashi Y, Inokuchi J. 2005 TNFa-induced insulin resistance in adipocytes as a membrane microdomain disorder: Involvement of ganglioside GM3. Glycobiology 15, 21-29. (doi: 10.1093/glycob/cwh135
127. Kabayama K, Sato T, Saito K, Loberto N, Prinetti A, Sonnino S, Kinjo M, Igarashi Y, Inokuchi J. 2007 Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl Acad. Sci. USA 104, 13 678-13 683. (doi: 10.1073/pnas.0703650104
128. Aerts JM et al. 2007 Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341-1349. (doi: 10.2337/db06-1619
129. Snook CF, Jones JA, Hannun YA. 2006 Sphingolipidbinding proteins. Biochim. Biophys. Acta 1761, 927-946. (doi: 10.1016/j.bbalip.2006.06.004
130. Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. 2002 Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J. Biol. Chem. 277, 11 292-11 296. (doi: 10.1074/jbc.M111679200
131. Bjorkholm P, Ernst AM, Hacke M, Wieland F, Brugger B, von Heijne G. 2014 Identification of novel sphingolipid-binding motifs in mammalian membrane proteins. Biochim. Biophys. Acta 1838, 2066-2070. (doi: 10.1016/j.bbamem.2014. 04.026
132. Melkonian KA, Ostermeyer AG, Chen JZ, Roth MG, Brown DA. 1999 Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J. Biol. Chem. 274, 3910-3917. (doi: 10. 1074/jbc.274.6.3910
133. Yang W, Di Vizio D, Kirchner M, Steen H, Freeman MR. 2010 Proteome scale characterization of human S-Acylated proteins in lipid raft-enriched and nonraft membranes. Mol. Cell. Proteomics 9, 54-70. (doi: 10.1074/mcp.M800448-MCP200
134. Wong W, Schlichter LC. 2004 Differential recruitment of Kv1.4 and Kv4.2 to lipid rafts by PSD-95. J. Biol. Chem. 279, 444-452. (doi: 10.1074/jbc.M304675200
135. Nitabach MN, Llamas DA, Araneda RC, Intile JL, Thompson IJ, Zhou YI, Holmes TC. 2001 A mechanism for combinatorial regulation of electrical activity: Potassium channel subunits capable of functioning as Src homology 3-dependent adaptors. Proc. Natl Acad. Sci. USA 98, 705-710. (doi: 10. 1073/pnas.031446198
136. Brenman JE et al. 1996 Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and a1-syntrophin mediated by PDZ domains. Cell 84, 757-767. (doi: 10.1016/S0092-8674(00)81053-3
137. Topinka JR, Bredt DS. 1998 N-Terminal palmitoylation of PSD-95 regulates association with cell membranes and interaction with K+ channel Kv1.4. Neuron 20, 125-134. (doi: 10.1016/S0896-6273(00)80440-7
138. Hicks DA, Nalivaeva NN, Turner AJ. 2012 Lipid rafts and Alzheimer's disease: Protein-lipid interactions and perturbation of signaling. Front. Physiol. 3, 189. (doi: 10.3389/fphys.2012.00189
139. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998 Cholesterol depletion inhibits the generation of b-Amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460-6464. (doi: 10.1073/pnas.95.11.6460
140. Amaro M, Sachl R, Aydogan G, Mikhalyov II, Vacha R, Hof M. 2016 GM1 Ganglioside inhibits b-Amyloid oligomerization induced by sphingomyelin. Angew. Chem. 55, 9411-9415. (doi: 10.1002/anie. 201603178
141. Horres CR, Hannun YA. 2012 The roles of neutral sphingomyelinases in neurological pathologies. Neurochem. Res. 37, 1137-1149. (doi: 10.1007/s11064-011-0692-y
142. He X, Huang Y, Li B, Gong CX, Schuchman EH. 2010 Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 31, 398-408. (doi: 10.1016/j.neurobiolaging.2008.05.010
143. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP. 2004 Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 2070-2075. (doi: 10. 1073/pnas.0305799101
144. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R. 2011 Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6, e21643. (doi: 10.1371/journal.pone.0021643
145. Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, Yang J, Duerksen-Hughes PJ. 2012 Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J. Alzheimer's Dis. 29, 537-547. (doi: 10.3233/jad-2011-111202
146. Katsel P, Li C, Haroutunian V. 2007 Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem. Res. 32, 845-856. (doi: 10. 1007/s11064-007-9297-x
147. Malm T, Loppi S, Kanninen KM. 2016 Exosomes in Alzheimer's disease. Neurochem. Int. 97, 193-199. (doi: 10.1016/j.neuint.2016.04.011
148. Dinkins MB, Enasko J, Hernandez C, Wang G, Kong J, Helwa I, Liu Y, Terry Jr AV, Bieberich E. 2016 Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer's disease pathology and improves cognition in the 5XFAD mouse. J. Neurosci. 36, 8653-8667. (doi: 10.1523/jneurosci.1429-16.2016
149. McLaurin J, Chakrabartty A. 1996 Membrane disruption by Alzheimer b-Amyloid peptides mediated through specific binding to either phospholipids or gangliosides: Implications for neurotoxicity. J. Biol. Chem. 271, 26 482-26 489. (doi: 10.1074/jbc.271.43.26482
150. Kakio A, Nishimoto S, Kozutsumi Y, Matsuzaki K. 2003 Formation of a membrane-Active form of amyloid b-protein in raft-like model membranes. Biochem. Biophys. Res. Commun. 303, 514-518. (doi: 10.1016/S0006-291X(03)00386-3
151. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. 2005 Structural membrane alterations in Alzheimer brains found to be associated with regional disease development: Increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergentresistant membrane domains. J. Neurochem. 92, 171-182. (doi: 10.1111/j.1471-4159.2004.02849.x
152. Ariga T, McDonald MP, Yu RK. 2008 Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease: A review. J. Lipid Res. 49, 1157-1175. (doi: 10.1194/jlr.R800007-JLR200
153. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G, Di Paolo G. 2012 Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678-2688. (doi: 10.1074/jbc.M111. 274142
154. Fukami Y, Ariga T, Yamada M, Yuki N. 2017 Brain gangliosides in Alzheimer's disease: Increased expression of cholinergic neuron-specific gangliosides. Curr. Alzheimer Res. 3, 145.
155. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. 2004 Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972-1977. (doi: 10.1056/NEJMoa033277
156. Sidransky E et al. 2009 Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661. (doi: 10.1056/NEJMoa0901281
157. Wu YR, Chen CM, Chao CY, Ro LS, Lyu RK, Chang KH, Lee-Chen GJ. 2007 Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J. Neurol. Neurosurg. Psychiatry 78, 977-979. (doi: 10.1136/jnnp.2006. 105940
158. Kumar KR et al. 2013 Glucocerebrosidase mutations in a Serbian Parkinson's disease population. Eur. J. Neurol. 20, 402-405. (doi: 10.1111/j.1468-1331.2012.03817.x
159. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH. 2012 Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72, 455-463. (doi: 10.1002/ana.23614
160. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM. 2014 Reduced glucocerebrosidase is associated with increased a-synuclein in sporadic Parkinson's disease. Brain J. Neurol. 137, 834-848. (doi: 10. 1093/brain/awt367
161. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. 2011 Gaucher disease glucocerebrosidase and asynuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52. (doi: 10.1016/j. cell.2011.06.001
162. Schlossmacher MG, Cullen V, Muthing J. 2005 The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 352, 728-731; author reply 728-731. (doi: 10.1056/NEJM200502173520719
163. Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AH. 2015 No evidence for substrate accumulation in Parkinson brains with GBA mutations. Movement Disorders 30, 1085-1089. (doi: 10.1002/mds.26278
164. Boutin M, Sun Y, Shacka JJ, Auray-Blais C. 2016 Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson disease. Anal. Chem. 88, 1856-1863. (doi: 10.1021/acs.analchem.5b04227
165. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL. 2005 A combinatorial code for the interaction of a-synuclein with membranes. J. Biol. Chem. 280, 31 664-31 672. (doi: 10.1074/jbc. M504894200
166. Fabelo N, Martin V, Santpere G, Marin R, Torrent L, Ferrer I, Diaz M. 2011 Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol. Med. 17, 1107-1118. (doi: 10.2119/molmed.2011.00119
167. Martinez Z, Zhu M, Han S, Fink AL. 2007 GM1 specifically interacts with a-synuclein and inhibits fibrillation. Biochemistry 46, 1868-1877. (doi: 10. 1021/bi061749a
168. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. 1992 Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 256, 843-846. (doi: 10.1126/science.1350379
169. Pope-Coleman A, Tinker JP, Schneider JS. 2000 Effects of GM1 ganglioside treatment on preand postsynaptic dopaminergic markers in the striatum of Parkinsonian monkeys. Synapse 36, 120-128. (doi: 10.1002/(sici)1098-2396(200005)36: 2,120: : Aid-syn5.3.0.co; 2-y
170. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, Luquin MR, Obeso JA, Del Rio J. 1993 GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTPtreated monkeys. Neuroscience 56, 965-972. (doi: 10.1016/0306-4522(93)90142-3
171. Zappia M et al. 2002 Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol. Scandinavica 106, 54-57. (doi: 10.1034/j.1600-0404.2002.01240.x
172. Ferlazzo E, Striano P, Italiano D, Calarese T, Gasparini S, Vanni N, Fruscione F, Genton P, Zara F. 2016 Autosomal recessive progressive myoclonus epilepsy due to impaired ceramide synthesis. Epileptic Disorders 18, 120-127. (doi: 10.1684/epd. 2016.0857
173. Mosbech MB et al. 2014 Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Ann. Clin. Transl. Neurol. 1, 88-98. (doi: 10.1002/acn3.28
174. Ginkel C et al. 2012 Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-Associated glycoprotein in oligodendrocytes. J. Biol. Chem. 287, 41 888-41 902. (doi: 10.1074/jbc.M112.413500
175. Imgrund S, Hartmann D, Farwanah H, Eckhardt M, Sandhoff R, Degen J, Gieselmann V, Sandhoff K, Willecke K. 2009 Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J. Biol. Chem. 284, 33 549-33 560. (doi: 10.1074/jbc.M109.031971
176. Pewzner-Jung Y et al. 2010 A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. J. Biol. Chem. 285, 10 902-10 910. (doi: 10.1074/jbc.M109. 077594
177. Silva LC, Ben David O, Pewzner-Jung Y, Laviad EL, Stiban J, Bandyopadhyay S, Merrill Jr AH, Prieto M, Futerman AH. 2012 Ablation of ceramide synthase 2 strongly affects biophysical properties of membranes. J. Lipid Res. 53, 430-436. (doi: 10. 1194/jlr.M022715
178. Zhou J et al. 2012 Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. Am. J. Human Genetics 91, 5-14. (doi: 10.1016/j.ajhg.2012. 05.001
179. Rubboli G et al. 2015 Spinal muscular atrophy associated with progressive myoclonic epilepsy: A rare condition caused by mutations in ASAH1. Epilepsia 56, 692-698. (doi: 10.1111/epi.12977
180. Gan JJ et al. 2015 Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. NMD 25, 959-963. (doi: 10.1016/j.nmd.2015.09.007
181. Dyment DA et al. 2014 Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy. Clin. Genetics 86, 558-563. (doi: 10.1111/cge.12307
182. Schuchman EH. 2016 Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. Biochim. Biophys. Acta 1862, 1459-1471. (doi: 10.1016/j.bbadis.2016. 05.001
183. Li CM et al. 2002 Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. Genomics 79, 218-224. (doi: 10.1006/geno.2002.6686
184. Young MM, Kester M, Wang HG. 2013 Sphingolipids: Regulators of crosstalk between apoptosis and autophagy. J. Lipid Res. 54, 5-19. (doi: 10.1194/jlr.R031278
185. Simpson MA et al. 2004 Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nature genetics. 36, 1225-1229. (doi: 10. 1038/ng1460
186. Fragaki K et al. 2013 Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. EJHG 21, 528-534. (doi: 10.1038/ejhg. 2012.202
187. Liu Y, Su Y, Wiznitzer M, Epifano O, Ladisch S. 2008 Ganglioside depletion and EGF responses of human GM3 synthase-deficient fibroblasts. Glycobiology 18, 593-601. (doi: 10.1093/glycob/cwn039
188. Pike LJ, Han X, Gross RW. 2005 Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids: A shotgun lipidomics study. J. Biol. Chem. 280, 26 796-26 804. (doi: 10.1074/jbc. M503805200
189. Yamashita T et al. 2005 Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl Acad. Sci. USA 102, 2725-2730. (doi: 10. 1073/pnas.0407785102
190. Yamashita T et al. 2003 Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl Acad. Sci. USA 100, 3445-3449. (doi: 10.1073/pnas. 0635898100
191. Sezgin E, Levental I, Mayor S, Eggeling C. In press. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. (doi: 10.1038/nrm.2017.16